Tafamidis

Specifications

594839-88-0CAS Number

813-715-5EC Number

2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acidIUPAC Name

C14H7Cl2NO3Chemical Formula

308.1 g/molMolecular Weight

TAFAMIDIS; 594839-88-0; Vyndamax; 2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid; FX-1006; tafamidisum; 8FG9H9D31J; 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid; CHEBI:78538; FX1006; FX-1005; DTXSID00208185; 6-Benzoxazolecarboxylic acid, 2-(3,5-dichlorophenyl)-; RefChem:56085; DTXCID20130676; N07XX08; 813-715-5; FX006; 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid; 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid; C14H7Cl2NO3; 2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid; MFCD16621109; Tafamidis [USAN]; Tafamidis [USAN:INN]; UNII-8FG9H9D31J; 4his; tafamidis-meglumine; Fx 1006; Vyndamax (TN); 3MI; 594839-88-0 (free acid); Vynmac (TN); TAFAMIDIS [INN]; TAFAMIDIS [JAN]; TAFAMIDIS [MI]; TAFAMIDIS [MART.]; TAFAMIDIS [WHO-DD]; Tafamidis (JAN/USAN/INN); SCHEMBL442508; GTPL8378; orb1302753; TAFAMIDIS [ORANGE BOOK]; CHEMBL2103837; PF-06291826(Tafamidis); SCHEMBL29361223; PF-06291826(Tafamidis)?; GLXC-10770; HMS3741E09; HMS5085B06; EX-A3575; BDBM50197883; EBC-06821; s6465; AKOS017550076; DB11644; FD27988; VS-0125; NCGC00390731-01; 137464-18-7; HY-14852; SY217402; DB-072645; NS00072572; T4565; C75776; D09673; EN300-307185; Q519447; BRD-K23728141-001-01-2; Z1443584665Synonyms